ReviewPaediatrics & child health2018
Human papillomavirus vaccine for children and adolescents.
Review in Paediatrics & child health, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 2 syntheses or guidelines pooled it, 21 citations in OpenAlex.
- ECTRIMS/EAN consensus on vaccination in people with multiple sclerosis: Improving immunization strategies in the era of highly active immunotherapeutic drugs.Multiple sclerosis (Houndmills, Basingstoke, England) · 2023Pooled it
- Assessment of School Anti-Bullying Interventions: A Meta-analysis of Randomized Clinical Trials.JAMA pediatrics · 2021Pooled it
- What do parents of school-aged children want to know about HPV vaccination in Canada? Results of an online survey on Facebook.Canada communicable disease report = Releve des maladies transmissibles au Canada · 2026Article
- 2025 update of the Greig Health Record: Part 1-what's new?Canadian family physician Medecin de famille canadien · 2026Review
- Estimating the Age of Disease-causal HPV Infection Based on the Natural History of CIN2+ Among Females in Canada.Open forum infectious diseases · 2025Article
- Knowledge and attitudes about human papillomavirus infection and prevention methods among medical science students in Novi Sad, Serbia: a cross-sectional study.BMC public health · 2025Article
- Stakeholders' perspectives on barriers to and facilitators of school-based HPV vaccination in the context of COVID-19 pandemic-related disruption: a qualitative mixed methods study.International journal of qualitative studies on health and well-being · 2024Article
- Knowledge about HPV Infection and the HPV Vaccine among Parents in Southeastern Serbia.Medicina (Kaunas, Lithuania) · 2022Article
- Human papillomavirus (HPV) vaccination across a cascade of knowledge, willingness, and uptake among gay, bisexual, and other men who have sex with men in Canada's three largest cities.Human vaccines & immunotherapeutics · 2021Article
- Newcomer knowledge, attitudes, and beliefs about human papillomavirus (HPV) vaccination.BMC family practice · 2021Article
- Reporting of financial conflicts of interest by Canadian clinical practice guideline producers: a descriptive study.CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne · 2020Article
- Low prevalence of p16-positive HPV-related head-neck cancers in Thailand: tertiary referral center experience.BMC cancer · 2019Article
- HPV Vaccine and College-Age Men: A Scoping Review.American journal of men's healthArticle
- The role of pharmacists in providing recommended vaccines.Canadian pharmacists journal : CPJ = Revue des pharmaciens du Canada : RPCReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Human papillomavirus (HPV) is known to cause genital warts, cervical cancer, penile cancer, anal cancer and oropharyngeal cancer. In North America, the lifetime cumulative incidence of HPV infection is estimated at more than 70% for all HPV types combined. A safe and effective vaccine against nine HPV types is available. HPV vaccine should be administered routinely to all girls and boys between the ages of 9 and 13 years of age. All youth who have not received the vaccine in a routine program should receive the vaccine in a 'catch-up' program. Physicians caring for children and youth should advocate for funding and implementation of universal HPV vaccine programs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.